|
1
|
Inamura K: Renal cell tumors:
Understanding their molecular pathological epidemiology and the
2016 WHO classification. Int J Mol Sci. 18(pii): E21952017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Koo KC and Chung BH: Epidemiology and
treatment patterns of urologic cancers in Korea. Korean J Urol
Oncol. 13:51–57. 2015.
|
|
3
|
Rini BI, Rathmell WK and Godley P: Renal
cell carcinoma. Curr Opin Oncol. 20:300–306. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Compare D and Nardone G: Contribution of
gut microbiota to colonic and extracolonic cancer development. Dig
Dis. 29:554–561. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pope JL, Tomkovich S, Yang Y and Jobin C:
Microbiota as a mediator of cancer progression and therapy. Transl
Res. 179:139–154. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ramezani A and Raj DS: The gut microbiome,
kidney disease, and targeted interventions. J Am Soc Nephrol.
25:657–670. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ramezani A, Massy ZA, Meijers B, Evenepoel
P, Vanholder R and Raj DS: Role of the gut microbiome in uremia: A
Potential therapeutic target. Am J Kidney Dis. 67:483–498. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li L, Ma L and Fu P: Gut
microbiota-derived short-chain fatty acids and kidney diseases.
Drug Des Devel Ther. 11:3531–3542. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chui CH, Cheng GY, Ke B, Lau FY, Wong RS,
Kok SH, Fatima S, Cheung F, Cheng CH, Chan AS and Tang JC: Growth
inhibitory potential of effective microorganism fermentation
extract (EM-X) on cancer cells. Int J Mol Med. 14:925–929.
2004.PubMed/NCBI
|
|
10
|
Yoon SP and Kim J: Exogenous CGRP
upregulates profibrogenic growth factors through PKC/JNK signaling
pathway in kidney proximal tubular cells. Cell Biol Toxicol.
34:251–262. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim JB, Hwang SE and Yoon SP:
Dexamethasone reduces side population fraction through
downregulation of ABCG2 transporter in MCF-7 breast cancer cells.
Mol Med Rep. 16:453–458. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Okada T and Yoneyama M: The interaction of
malignant cells with yeast. II. A new yeast extract inhibiting the
growth of malignant cell. Hiroshima J Med Sci. 19:99–117.
1970.PubMed/NCBI
|
|
13
|
Fardon JC, Poydock ME and Tsuchiya Y:
Response of neoplastic and non-neoplastic cells to a yeast extract.
J Surg Oncol. 10:10–21. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Poydock ME, Fardon JC, Tsuchiya Y and Cook
ES: Selective effect of fractions of a yeast extract (PCO) on
normal and malignant cells. Exp Cell Biol. 46:231–239.
1978.PubMed/NCBI
|
|
15
|
Heffeter P, Jakupec MA, Körner W, Wild S,
von Keyserlingk NG, Elbling L, Zorbas H, Korynevska A, Knasmüller
S, Sutterlüty H, et al: Anticancer activity of the lanthanum
compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate
(KP772; FFC24). Biochem Pharmacol. 71:426–440. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim KH, Rodriguez AM, Carrico PM and
Melendez JA: Potential mechanisms for the inhibition of tumor cell
growth by manganese superoxide dismutase. Antioxid Redox Signal.
3:361–373. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang WS, SriRamaratnam R, Welsch ME,
Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji
AF, Clish CB, et al: Regulation of ferroptotic cancer cell death by
GPX4. Cell. 156:317–331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Friedmann Angeli JP, Schneider M, Proneth
B, Tyurina YY, Tyurin VA, Hammond VJ, Herbach N, Aichler M, Walch
A, Eggenhofer E, et al: Inactivation of the ferroptosis regulator
Gpx4 triggers acute renal failure in mice. Nat Cell Biol.
16:1180–1191. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kazan HH, Urfali-Mamatoglu C and Gunduz U:
Iron metabolism and drug resistance in cancer. Biometals.
30:629–641. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu H, Guo P, Xie X, Wang Y and Chen G:
Ferroptosis, a new form of cell death, and its relationships with
tumourous diseases. J Cell Mol Med. 21:648–657. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Martin-Sanchez D, Poveda J,
Fontecha-Barriuso M, Ruiz-Andres O, Sanchez-Niño MD, Ruiz-Ortega M,
Ortiz A and Sanz AB: Targeting of regulated necrosis in kidney
disease. Nefrologia. 38:125–135. 2018.(In English, Spanish).
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fanzani A and Poli M: Iron, oxidative
damage and ferroptosis in rhabdomyosarcoma. Int J Mol Sci. 18(pii):
E17182017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pfeifhofer-Obermair C, Tymoszuk P, Petzer
V, Weiss G and Nairz M: Iron in the tumor
microenvironment-connecting the dots. Front Oncol. 8:5492018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Golčić M and Petković M: Changes in
metabolic profile, iron and ferritin levels during the treatment of
metastatic renal cancer-A new potential biomarker? Med Hypotheses.
94:148–150. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu CC, Chen KK, Chen MT, Huang JK, Lin AT,
Lee YH and Chang LS: Serum iron as a tumor marker in renal cell
carcinoma. Eur Urol. 19:54–58. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Partin AW, Criley SR, Steiner MS, Hsieh K,
Simons JW, Lumadue J, Carter HB and Marshall FF: Serum ferritin as
a clinical marker for renal cell carcinoma: Influence of tumor
volume. Urology. 45:211–217. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kirkali Z, Esen AA, Kirkali G and Güner G:
Ferritin: A tumor marker expressed by renal cell carcinoma. Eur
Urol. 28:131–134. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Torti SV and Torti FM: Ironing out cancer.
Cancer Res. 71:1511–1514. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Latunde-Dada GO: Ferroptosis: Role of
lipid peroxidation, iron and ferritinophagy. Biochim Biophys Acta
Gen Subj. 1861:1893–1900. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Santoni M, De Tursi M, Felici A, Lo Re G,
Ricotta R, Ruggeri EM, Sabbatini R, Santini D, Vaccaro V and
Milella M: Management of metastatic renal cell carcinoma patients
with poor-risk features: Current status and future perspectives.
Expert Rev Anticancer Ther. 13:697–709. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bayeva M, Khechaduri A, Puig S, Chang HC,
Patial S, Blackshear PJ and Ardehali H: mTOR regulates cellular
iron homeostasis through tristetraprolin. Cell Metab. 16:645–657.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Brodaczewska KK, Szczylik C, Fiedorowicz
M, Porta C and Czarnecka AM: Choosing the right cell line for renal
cell cancer research. Mol Cancer. 15:832016. View Article : Google Scholar : PubMed/NCBI
|
